Hagop M Kantarjian Selected Research

Blast Crisis (Blast Phase)

6/2021	Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
1/2020	Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
12/2017	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.
11/2017	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
8/2017	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
10/2016	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
10/2015	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
9/2015	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
5/2013	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
10/2012	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hagop M Kantarjian Research Topics

Disease

151	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 06/2002
136	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 03/2002
98	Neoplasms (Cancer) 01/2022 - 07/2002
84	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2022 - 01/2002
79	Philadelphia Chromosome 09/2022 - 04/2002
73	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 05/2002
72	Leukemia 01/2022 - 02/2002
31	Primary Myelofibrosis (Myelosclerosis) 10/2020 - 04/2003
26	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2002
20	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 04/2003
20	Blast Crisis (Blast Phase) 06/2021 - 05/2002
19	Thrombocytopenia (Thrombopenia) 11/2021 - 09/2002
19	Residual Neoplasm 01/2021 - 01/2003
15	Neutropenia 11/2021 - 06/2003
14	Disease Progression 01/2021 - 03/2002
14	Exanthema (Rash) 01/2021 - 03/2003
14	Diarrhea 01/2019 - 08/2002
12	Infections 10/2021 - 01/2002
12	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 06/2002
12	Anemia 01/2019 - 04/2002
11	Fibrosis (Cirrhosis) 01/2022 - 07/2005
11	Acute Promyelocytic Leukemia 01/2022 - 06/2002
11	Fatigue 01/2021 - 04/2003
11	Splenomegaly 01/2019 - 10/2004
10	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 04/2004
9	Lymphoma (Lymphomas) 01/2019 - 12/2003
8	Febrile Neutropenia 11/2021 - 02/2010
8	Polycythemia Vera 01/2017 - 06/2006
7	Cytopenia 01/2021 - 05/2006
7	Pleural Effusion (Pleural Effusions) 01/2020 - 06/2005
7	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 07/2015 - 04/2003
6	Pneumonia (Pneumonitis) 01/2022 - 09/2007
6	Pathologic Complete Response 01/2019 - 06/2002
6	Nausea 01/2018 - 09/2003
5	Hairy Cell Leukemia 01/2022 - 12/2003
5	Edema (Dropsy) 01/2019 - 08/2002
5	Vomiting 01/2019 - 09/2003
5	Fever (Fevers) 01/2018 - 06/2005
5	Essential Thrombocythemia 10/2017 - 06/2006
5	Headache (Headaches) 11/2015 - 04/2003
5	Pain (Aches) 10/2014 - 04/2003

Drug/Important Bio-Agent (IBA)

90	Imatinib Mesylate (Gleevec)FDA Link 07/2021 - 03/2002
68	Tyrosine Kinase InhibitorsIBA 09/2022 - 09/2003
47	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 04/2002
35	Decitabine FDA Link 12/2021 - 08/2003
33	Dasatinib (BMS 354825)FDA Link 05/2022 - 02/2007
31	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2002
29	venetoclaxIBA 11/2022 - 12/2015
27	nilotinib FDA Link 07/2021 - 02/2007
25	Pharmaceutical PreparationsIBA 01/2022 - 08/2002
25	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 05/2002
22	ruxolitinibIBA 10/2020 - 01/2009
19	Phosphotransferases (Kinase)IBA 01/2019 - 11/2005
18	Inotuzumab OzogamicinIBA 01/2022 - 08/2016
15	blinatumomabIBA 09/2022 - 03/2014
15	Clofarabine (Clolar)FDA Link 02/2017 - 03/2003
14	Rituximab (Mabthera)FDA Link 01/2022 - 04/2003
13	bosutinibIBA 06/2021 - 05/2011
13	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 01/2002
13	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2002
13	bcr-abl Fusion ProteinsIBA 01/2020 - 03/2002
12	fludarabineIBA 01/2022 - 04/2002
12	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2021 - 06/2002
12	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2002
11	NucleosidesIBA 06/2014 - 02/2002
10	ponatinibIBA 05/2022 - 06/2013
10	Monoclonal AntibodiesIBA 01/2021 - 04/2003
10	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 06/2002
9	Interferon-alpha (Interferon Alfa)IBA 02/2008 - 04/2002
8	Reticulin (Reticular Fiber)IBA 01/2022 - 07/2005
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2002
8	Lenalidomide (CC 5013)FDA Link 01/2021 - 08/2006
8	CytokinesIBA 01/2020 - 07/2003
7	Gemtuzumab (Mylotarg)FDA Link 01/2022 - 06/2002
7	enasidenibIBA 01/2022 - 10/2017
7	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 04/2003
6	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 06/2002
6	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 09/2004
6	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 05/2009
6	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021 - 01/2002
6	MethyltransferasesIBA 01/2021 - 08/2007
6	Transaminases (Aminotransferases)IBA 01/2020 - 01/2008
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 05/2002
6	Janus Kinase 2IBA 01/2019 - 11/2005
6	Hemoglobins (Hemoglobin)IBA 02/2014 - 04/2002
6	Janus Kinase InhibitorsIBA 02/2014 - 01/2013
6	Biological ProductsIBA 03/2013 - 07/2002
6	troxacitabineIBA 01/2007 - 02/2002
5	fms-Like Tyrosine Kinase 3IBA 01/2022 - 10/2012
5	NucleophosminIBA 01/2021 - 10/2009
5	Histone Deacetylase InhibitorsIBA 12/2017 - 11/2006
5	InterferonsIBA 01/2017 - 06/2003
5	HomoharringtonineIBA 01/2016 - 04/2002

Therapy/Procedure

208	Therapeutics 09/2022 - 04/2002
57	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
14	Salvage Therapy 01/2021 - 10/2008
12	Stem Cell Transplantation 12/2019 - 09/2002
10	Induction Chemotherapy 01/2022 - 01/2002
9	Drug Tapering 01/2020 - 06/2003
7	Aftercare (After-Treatment) 06/2021 - 08/2002